1 / 16

Christine Lubinski Vice President for Global Health Infectious Diseases Society of America

Germs Go Global Tuberculosis and HIV/TB Co-Infection. Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009. Global Tuberculosis Pandemic. Second leading infectious disease killer worldwide One-third of the world’s population is

alena
Download Presentation

Christine Lubinski Vice President for Global Health Infectious Diseases Society of America

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Germs Go Global Tuberculosis and HIV/TB Co-Infection Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009

  2. Global Tuberculosis Pandemic • Second leading infectious disease killer • worldwide • One-third of the world’s population is • infected • 9.27 million new cases in 2007 • An estimated 1.37 million of these cases • were HIV-positive • 79% of HIV+ cases in Africa • 1.8 million deaths in 2007, including almost • 500,000 among HIV infected persons • 500,000 cases of MDR-TB in 2007 • By the end of 2008, 55 countries reported • at least one case of XDR-TB

  3. HIV/TB Co-Infection: Deadly Synergy • HIV infection facilitates active • TB disease in those with latent TB • IPT effective but not available to • most in need • HIV epidemic has amplified the • TB epidemic in dual burden • countries- expanded TB risk to the • community at large • TB is more difficult to diagnose in • persons with HIV and is also more • challenging to treat • TB expedites HIV disease • progression • TB patients continue to have • limited ART access • TB is the leading cause of death • among persons with HIV • TB undermining US efforts to • save lives from AIDS in Africa

  4. Estimated Tuberculosis Incidence Rates, by Country, in 2007

  5. Estimated HIV Prevalence in new Tuberculosis cases in 2007

  6. Tuberculosis: Antiquated tools fordiagnosis, treatment and prevention • Diagnostics- • Detect only half of people tested and • fewer than 20% of HIV patients with • active TB • Tests for drug resistant • strains not available in • most of the developing • world • Drugs- • 4 drugs must be taken for 6-9 months– • significant side effects, not compatible • with important anti-HIV drugs • Drug resistant TB requires • 2 years of treatment with • highly toxic drugs, which are • frequently not available in • developing countries • Vaccine- • existing vaccine does not protect past • infancy, and is not recommended in infants • with HIV infection

  7. Tuberculosis Research & Development • $482.5 million spent worldwide in 2007, far short of • WHO goals of $900 million per year • TB drugs received highest level of funding at $170 mil • US diagnostic research is grossly underfunded at • $41.9 million, as is operational research at $36.8 • million • Top Funder– NIAID/NIH at $160 million • No.2 funder– Bill & Melinda Gates Foundation at • $124 million in 2007. Gates Foundation funding • outpaced NIH in all categories except for basic • research Treatment Action Group: TB Research and Development: A Critical Analysis of Funding Trends, 2005-2007 An Update

  8. Tuberculosis in the United States 12,898 new cases were reported in 2008 125 cases of MDR-TB 58% of cases were foreign born; Among US-born populations blacks have TB rate 7 times higher than whites Progress toward TB elimination has slowed down Over the last 3 years, more than 1000 jobs have been lost in state TB control programs

  9. Annual CDC TB Budget, FY 1990–FY 2008 (2008 budget 40% lower than 1994, in CPI-Adjusted dollars*) Actual $ CPI-Adjusted Source: Center for Disease Control and Prevention * Adjusted to 1990 dollars by Consumer Price Index for Medical Care, includes TB/HIV and lab dollars

  10. New Legislative Authorities* • Comprehensive TB Elimination Act: • $200 million for TB prevention, control, and new tools FY 2009-2013 • Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act: • $4 billion for global TB prevention FY 2009-2013 *Not yet appropriated

  11. Fund the Comprehensive TB Elimination Act : Public Law 110-392 • Authorizes $200 million for TB prevention, control • and new tools FY 2009-2013 • Shore up state TB control programs • Enhance US capacity to address drug-resistant • TB • Facilitate development of new “tools”- drugs, • diagnostics, vaccines • Current TB funding is inadequate for testing • diagnostics, drugs, and vaccines currently in • pipeline in Phase III trials

  12. Advancing TB R&D and Global TB Control • Double TB research Spending to $320 million at • NIH, providing resources for clinical trials, • diagnostics and research agenda for drug-resistant • TB • $100 million for CDC TB R & D • Provide $2.7 Billion to the Global Fund– largest • funding of global TB control • Enhance USAID TB Spending to $650 million to • Implement Lantos/Hyde • Increase operational research through USAID • and OGAC • Implement recommendations of the Federal TB • Task force to respond to MDR-TB domestically • and globally

  13. HIV/TB: US ResponseFund Lantos-Hyde • Continue scale-up of HIV treatment, which • reduces TB morbidity/mortality in PWHIV • Fund the Global Fund to Fight HIV, TB and • Malaria at $2.7 billion- leading global funder • of TB control. • Ensure that TB screening, treatment and • preventive therapy are standard of care at • PEPFAR-funded HIV clinics • Stop TB transmission in HIV clinics by • Implementing infection control strategies

  14. Antimicrobial-Resistant Strains Spread Rapidly MRSA = methicillin-resistant Staphylococcus aureus; VRE = Vancomycin-resistant enteroccoci; FQRP =Fluoroquinolone-resistant Pseudomonas aeruginosa Source: Centers for Disease Control and Prevention Crisis in Antimicrobial Resistance

  15. Strategies to Address Antimicrobial Resistance (STAAR) Act To Strengthen Federal Antimicrobial Resistance Surveillance, Research and Prevention & Control Working Together We Can Enact the STAAR Act!!

  16. IDSA’s 2004 Report: “Bad Bugs, No Drugs (BBND): As Antibiotic Discovery Stagnates, A Public Health Crisis Brews” “Only 16 new antibacterials are in late-stage clinical development at this time.” -- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America (Clinical Infectious Disease 2009:48; January 1, 2009)

More Related